8-K: Incannex Announces Positive Topline Results from Phase 2 Psilocybin Trial for Generalized Anxiety Disorder

Incannex Healthcare's Phase 2 trial of psilocybin-assisted therapy for generalized anxiety disorder demonstrated a statistically significant reduction in anxiety symptoms compared to placebo.

Summary

• Incannex Healthcare has announced positive topline results from its Phase 2 Psi-GAD1 clinical trial of psilocybin for generalized anxiety disorder.
• The trial met its primary endpoint, showing a statistically significant reduction in anxiety symptoms in the psilocybin group compared to the placebo group.
• The psilocybin group experienced a 12.8-point reduction in HAM-A scores from baseline, compared to a 3.6-point reduction in the placebo group, a 9.2-point improvement over placebo.
• 44% of patients in the psilocybin group showed at least a 50% reduction in anxiety scores, while 27% achieved full disease remission.
• The remission rate in the psilocybin group was more than five times higher than that of the placebo group.
• The newly developed psilocybin drug product, PSX-001, has been finalized, and cGMP manufacturing for clinical trial supply is underway.
• Incannex plans to submit an Investigational New Drug (IND) application to the FDA to proceed to a multi-site Phase 2B trial.

Sentiment

Score: 9

Explanation: The document presents very positive results from a Phase 2 clinical trial, with strong statistical significance and a high remission rate. The tone is optimistic and forward-looking, indicating a high likelihood of positive market reaction.

Positives

• The trial demonstrated a large clinical effect in the psilocybin treatment group over the placebo group.
• The reduction in HAM-A scores in the psilocybin group was significantly greater than those reported from trials on established medicines for anxiety.
• The improvement in anxiety scores is comparable to that seen in studies investigating psilocybin for depression.
• Psilocybin was well-tolerated, with only mild and moderate adverse events reported.
• No serious or severe adverse events were observed during the trial.
• Only one participant withdrew from the trial during the 7-week treatment program.

Risks

• The company needs to obtain FDA clearance for its IND application to conduct the Phase 2B trial in the US.
• Regulatory approvals are required from the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for the Phase 2B trial.
• The company is still in the clinical trial phase and there is no guarantee of future success.

Future Outlook

Incannex plans to submit an IND application to the FDA to proceed to a multi-site Phase 2B trial, PsiGAD2, in the US and UK. The company is also working on the cGMP manufacture of its psilocybin drug product, PSX-001.

Management Comments

• We are thrilled with the results from our initial PsiGAD trial, said President and CEO Joel Latham.
• This is the first time psilocybin has been investigated for treatment of generalised anxiety disorder, and the reduction in HAM-A scores we have observed are far greater those reported from trials on established medicines for treatment of anxiety.
• The safety and efficacy results from PsiGAD1 implore us to continue the development of PsiGAD through large scale well-controlled trials, because this treatment method has the potential to improve the quality of life for millions of people suffering from generalised anxiety disorder.

Industry Context

This announcement is significant as it highlights the potential of psilocybin-assisted therapy as a novel treatment for generalized anxiety disorder, an area with limited effective treatment options. The results are promising compared to existing treatments and other psilocybin studies for depression.

Comparison to Industry Standards

• The study's results show a 9.2-point improvement over placebo in HAM-A scores, which is significantly better than the -3.6 point improvement seen with quetiapine, a leading medication for GAD, as reported in a meta-analysis published in The Lancet.
• The 44% response rate and 27% remission rate in the psilocybin group are substantially higher than the rates typically observed with traditional treatments for GAD.
• The results are comparable to the magnitude of change seen in studies investigating psilocybin for treatment of depression disorders, suggesting a potential for broader application of this therapy.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results.
• Patients suffering from generalized anxiety disorder may benefit from this new treatment option.
• The company's employees and partners are likely to be encouraged by the positive results.

Next Steps

• Incannex will submit an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA).
• The company will proceed to a multi-site Phase 2B trial, PsiGAD2, in the US and UK.
• Incannex will continue to work with Clerkenwell Health to select trial sites and prepare regulatory documents for submission to the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK.
• The company will finalize the cGMP manufacture of its psilocybin drug product, PSX-001.

Key Dates

Keywords

psilocybin, generalized anxiety disorder, clinical trial, Phase 2, HAM-A, anxiety, FDA, IND, PSX-001, cGMP, remission, psychotherapy